Pathfinder Cell Therapy (OTCMKTS:PFND) & Establishment Labs (NASDAQ:ESTA) Head-To-Head Analysis

Establishment Labs (NASDAQ:ESTA) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares Establishment Labs and Pathfinder Cell Therapy”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$165.15 million	7.30	-$78.50 million	($2.58)	-16.70
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Establishment Labs.

Insider and Institutional Ownership

72.9% of Establishment Labs shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Establishment Labs and Pathfinder Cell Therapy, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	0	1	4	0	2.80
Pathfinder Cell Therapy	0	0	0	0	0.00

Establishment Labs currently has a consensus price target of $60.60, suggesting a potential upside of 40.67%. Given Establishment Labs’ stronger consensus rating and higher probable upside, analysts clearly believe Establishment Labs is more favorable than Pathfinder Cell Therapy.

Profitability

This table compares Establishment Labs and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-46.13%	-184.55%	-24.81%
Pathfinder Cell Therapy	N/A	N/A	N/A

Summary

Establishment Labs beats Pathfinder Cell Therapy on 5 of the 9 factors compared between the two stocks.

About Establishment Labs

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.